日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study

低剂量 CD7 嵌合抗原受体 T 细胞治疗复发/难治性 T 细胞淋巴瘤：一项单臂、开放标签的 Ia/Ib 期研究

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-026-01476-0
Yang, Fan; Liu, Rui; Fu, Zhonghua; Guo, Yuelu; Ma, Lixia; Cao, Miaomiao; Deng, Biping; Chang, Alex H; Wu, Haifeng; Gan, Shilin; Chen, Chen; Ke, Xiaoyan; Hu, Kai
CD7
T细胞
信号转导
淋巴瘤
细胞生物学
发表日期：2026
文献求助 收藏

Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort study

BCMA CAR-T细胞疗法及其后续策略在难治性和复发性浆细胞白血病中的疗效：一项回顾性队列研究

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2026.1756209
Guo, Yuelu; Ma, Lixia; Yang, Fan; Fu, Zhonghua; Li, Danyang; Liu, Rui; Cao, Miaomiao; Wei, Bian; Dou, Yimeng; Deng, Biping; Gan, Shilin; Chang, Alex H; Ke, Xiaoyan; Hu, Kai
T细胞
白血病
T细胞
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy.

Zanubrutinib 通过抑制 BTK 磷酸化、调节 PI3K/AKT/mTOR 通路和促进自噬来增强 CD19 CAR T 对 B 细胞淋巴瘤的杀伤作用。

期刊:Blood Science
影响因子:2.7
doi:10.1097/BS9.0000000000000276
Yao Hao, Qiu Ling, Ren Shi-Hui, Chen Dan, Li Meng-Jiao, Dou Bai-Tao, Zhang Nan, Wang Xiao, Su Yi, Chang Alex H, Fan Fang-Yi
mTOR
T细胞
信号转导
淋巴瘤
BTK
磷酸化
细胞生物学
AKT
自噬
CD19
发表日期：2026
文献求助 收藏

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial

BCMA/GPRC5D双特异性CAR T细胞疗法治疗复发/难治性髓外转移性多发性骨髓瘤：一项单中心、单臂I期临床试验

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-025-01713-2
Yao, Hao; Ren, Shi-Hui; Wang, Lin-Hui; Ren, Ming-Qiang; Cai, Jiao; Chen, Dan; He, Ying; Lai, Si-Han; Dou, Bai-Tao; Li, Meng-Jiao; Li, Yan-Ling; Cen, Ya-Li; Chang, Alex H; Su, Yi; Qiu, Ling; Fan, Fang-Yi
T细胞
多发性骨髓瘤
T细胞
骨髓瘤
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial

更正：BCMA/GPRC5D双特异性CAR T细胞疗法治疗复发/难治性髓外多发性骨髓瘤：一项单中心、单臂I期试验

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-025-01714-1
Yao, Hao; Ren, Shi-Hui; Wang, Lin-Hui; Ren, Ming-Qiang; Cai, Jiao; Chen, Dan; He, Ying; Lai, Si-Han; Dou, Bai-Tao; Li, Meng-Jiao; Li, Yan-Ling; Cen, Ya-Li; Chang, Alex H; Su, Yi; Qiu, Ling; Fan, Fang-Yi
T细胞
多发性骨髓瘤
T细胞
骨髓瘤
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial

达沙替尼联合CAR-T细胞疗法治疗新诊断的费城染色体阳性急性淋巴细胞白血病：一项非随机临床试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2025.0674
Zhang, Mingming; Fu, Shan; Feng, Jingjing; Hong, Ruimin; Wei, Guoqing; Zhao, Houli; Zhao, Mengyu; Xu, Huijun; Cui, Jiazhen; Huang, Simao; Wu, Xiaoyu; Liu, Lianxuan; Sun, Jie; Wu, Wenjun; Zhu, Yuanyuan; He, Jingsong; Zhao, Yi; Cai, Zhen; Zheng, Weiyan; Ye, Xiujin; Shi, Jimin; Luo, Yi; Wang, Dongrui; Chang, Alex H; Hu, Yongxian; Huang, He
T细胞
白血病
T细胞
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result

CAR-T治疗后复发/难治性急性淋巴细胞白血病患者序贯异基因造血干细胞移植：一项长期随访研究结果

期刊:Journal of Advanced Research
影响因子:13
doi:10.1016/j.jare.2025.02.006
Yang, Tingting; Dong, Yetian; Shi, Jimin; Zhang, Mingming; Kong, Delin; Feng, Jingjing; Fu, Shan; Xiao, Pingnan; Hong, Ruimin; Xu, Huijun; Luo, Yi; Zhao, Yanmin; Yu, Jian; Lai, Xiaoyu; Liu, Lizhen; Fu, Huarui; Ye, Yishan; Cui, Dawei; Cui, Jiazhen; Huang, Simao; Wei, Guoqing; Chang, Alex H; Huang, He; Hu, Yongxian
白血病
细胞生物学
发育与干细胞
干细胞
发表日期：2025
文献求助 收藏

Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial

在复发/难治性T细胞急性淋巴细胞白血病（T-ALL）患儿中，无需T细胞预筛选即可生成的自体CD7 CAR-T细胞：一项I期试验

期刊:Molecular Therapy
影响因子:12
doi:10.1016/j.ymthe.2024.09.006
Zhao, Liping; Li, Chuo; Zuo, Shiyu; Han, Yajing; Deng, Biping; Ling, Zhuojun; Zhang, Yanlei; Peng, Shuixiu; Xu, Jinlong; Duan, Jiajia; Wang, Zelin; Yu, Xinjian; Zheng, Qinlong; Xu, Xiuwen; Yuan, Ying; Tian, Zhenglong; Tang, Kaiting; Zhang, Yibing; Niu, Qing; Zhang, Jiecheng; Chang, Alex H; Luo, Yuechen; Feng, Xiaoming; Pan, Jing
CD7
T细胞
白血病
T细胞
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Five-year outcome of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation

CD19 后序贯 CD22 嵌合抗原受体 T 细胞疗法治疗异基因移植后复发的 B 细胞急性淋巴细胞白血病患者的五年疗效

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2024.286534
Liu, Shuangyou; An, Lihong; Yin, Zhichao; Lin, Yuehui; Ling, Zhuojun; Deng, Biping; Yu, Xinjian; Zheng, Qinlong; Zhao, Defeng; Wu, Tong; Chang, Alex H; Tong, Chunrong
T细胞
信号转导
白血病
CD22
细胞生物学
CD2
CD19
发表日期：2025
文献求助 收藏

Correction: Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma

更正：病例报告：CAR-T疗法治疗原发性小脑ALK阴性间变性大细胞淋巴瘤

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2025.1674954
Zou, Zhongqing; Lai, Sihan; Yi, Hai; Zhang, Qian; Yao, Hao; Yang, Hui; Zhang, Ling; Chang, Alex H; Su, Yi; Rao, Jin
ALK
细胞生物学
淋巴瘤
神经科学
发表日期：2025
文献求助 收藏